Advertisement

Iodinated contrast-induced acute kidney injury. Pathophysiology and prevention

Iodinated contrast-induced acute kidney injury. Pathophysiology and prevention

Danno renale acuto da mezzi iodati di contrasto. Fisiopatologia e suggerimenti di prevenzione

G Tec Nefrol Dial 2017; 29(1): 11 - 19

Article Type: REVIEW

Article Subject: AREA NEFROLOGICA

DOI:10.5301/GTND.2017.16584

Authors

Michele Andreucci

Abstract

The term acute renal failure (ARF) secondary to ischemic/nephrotoxic injury should no longer be used and be replaced by acute kidney injury (AKI), indicating an abrupt (within 24-48 hours) increase in serum creatinine by 0.5 mg/dL or by 25% above baseline. Replacing “failure” with “injury” served to include the entire range of renal impairment from small changes in serum creatinine to complete loss of renal function. The term ARF should be limited to a decrease in renal function so severe as to require dialysis. When AKI is due to radiographic contrast agents, it is called contrast-induced (CI) AKI. The pathogenesis of CI-AKI is complex and not well known. Many factors are involved, including hemodynamic changes such as renal vasoconstriction, particularly in the outer medulla where tubular segments devoted to active sodium reabsorption are located; the vasoconstriction may be due to direct action of the contrast agent but may also be mediated by stimulation of angiotensin II and adenosine, or by a decrease in the local production of prostaglandins and nitric oxide, all leading to medullary hypoxia. Other factors are osmotic diuresis (with increased tubular reabsorption of sodium and tubular epithelium injury, both worsening medullary hypoxia) and production of reactive oxygen species that will cause endothelial and epithelial damage, likewise worsening medullary hypoxia. The fall in renal blood flow and tubular obstruction will decrease the glomerular filtration rate. Treatment and prevention of CI-AKI are based on opposing these factors by adequate hydration; administration of furosemide along with fluid replacement; theophylline and aminophylline; PGE1 and PGI2; N-acetylcysteine, ascorbic acid and vitamin E; nebivolol and statins.

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Andreucci, Michele [PubMed] [Google Scholar]
    Professore Associato dell’Università “Magna Graecia” di Catanzaro, Cattedra di Nefrologia, Dipartimento di “Scienze della Salute”, Campus “Salvatore Venuta”, Università “Magna Graecia”, Catanzaro

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.